| Metric | This Period | Prior Year Period | YoY |
|---|---|---|---|
| Revenue / Net Sales | ¥372.1B | ¥330.6B | +12.5% |
| Operating Income | ¥102.3B | ¥84.4B | +21.2% |
| Ordinary Income | ¥109.4B | ¥72.4B | +51.1% |
| Net Income | ¥79.1B | ¥49.6B | +59.4% |
| ROE | 5.4% | 3.5% | - |
For the Q1 of FY ending March 2027, the company reported Revenue of ¥372.1B (YoY +¥41.5B, +12.5%), Operating Income of ¥102.3B (YoY +¥17.9B, +21.2%), Ordinary Income of ¥109.4B (YoY +¥37.0B, +51.1%), and Quarterly Net Income attributable to owners of the parent of ¥82.1B (YoY +¥29.5B, +56.0%), achieving both top-line and bottom-line growth. Gross margin improved to 43.1% (prior year 40.6%), up 246bp, and operating margin rose to 27.5% (prior year 25.5%), up 195bp, indicating marked profitability improvement. The core Semiconductor & FPD-related Equipment business accounted for 99.6% of revenue and maintained high profitability with an operating margin of 29.2%. Progress against full-year guidance was 23.4% for Revenue, 26.8% for Operating Income, 28.6% for Ordinary Income, and 29.5% for Net Income, indicating profit outperformance relative to plan.
[Revenue] Revenue increased to ¥372.1B (YoY +12.5%). The core Semiconductor & FPD-related Equipment business drove the performance with ¥371.1B (+12.5%), representing 99.6% of total sales. By region, the top three were the U.S. ¥110.7B (composition 29.8%), Taiwan ¥99.9B (26.8%), and China ¥92.4B (24.8%). U.S. sales rose substantially YoY +34.9%, Taiwan +4.3%, and China +7.9%. Korea recorded ¥20.3B (+26.6%), and other regions ¥26.1B, capturing demand across a wide geography. Domestic (Japan) sales were ¥22.8B (composition 6.1%) and remained flat. The Life Sciences business was ¥1.3B (+19.1%)—small but continuing growth—with limited contribution to consolidated revenue.
[Profitability] Cost of sales was ¥211.7B, yielding a gross margin of 43.1% (prior year 40.6%), an improvement of 246bp. SG&A was ¥58.1B (prior year ¥49.9B, +16.5%), resulting in an SG&A-to-sales ratio of 15.6% (prior year 15.1%), up 51bp; however, the gross margin improvement absorbed SG&A increases, and operating margin improved to 27.5% (+195bp). Operating Income was ¥102.3B (+21.2%). Non-operating income totaled ¥11.3B (including ¥10.4B foreign exchange gains), and non-operating expenses were ¥4.2B (including ¥12.3B foreign exchange losses and ¥0.6B interest expense), resulting in net non-operating income of +¥7.1B. Foreign exchange effects included both gains and losses, with a net impact limited to approximately -¥1.9B. Ordinary Income rose to ¥109.4B (+51.1%), outpacing Operating Income. Extraordinary items were minor: extraordinary income ¥0.0B and extraordinary loss ¥0.1B (impairment of fixed assets). Profit before income taxes was ¥109.3B; after deducting income taxes of ¥30.2B (effective tax rate 27.6%) and adjusting for non-controlling interests of -¥3.0B, Net Income attributable to owners of the parent was ¥82.1B (+56.0%). Net margin improved materially to 22.1% (prior year 15.9%), a 614bp improvement, resulting in reported top-line and bottom-line growth.
The Semiconductor & FPD-related Equipment segment reported Revenue ¥371.1B (YoY +12.5%), Operating Income ¥108.3B (+23.3%), and margin 29.2% (prior year 26.6%), enhancing profitability as the core business. Segment profit is presented on a pre-allocation basis; compared with consolidated Operating Income of ¥102.3B, segment profit of ¥108.3B less corporate allocations of ¥4.8B reconciles to consolidated results. The Life Sciences segment recorded Revenue ¥1.3B (+19.1%) but an operating loss of ¥1.2B (worse by 8.2% from prior year loss ¥1.1B), remaining in deficit with a margin of -90.8% as it is still in an investment phase. Impact on consolidated profit is limited, but accelerating growth toward profitability remains a challenge.
[Profitability] Operating margin was 27.5% (prior year 25.5%, +195bp) and Net margin 22.1% (prior year 15.9%, +614bp), both at high levels. Gross margin of 43.1% (prior year 40.6%, +246bp) reflects product mix and cost improvements. SG&A ratio was 15.6% (prior year 15.1%, +51bp), where scale effects from higher sales partially absorbed expense increases. [Capital Efficiency] ROE of 5.4% annualizes to approximately 21.6% and indicates efficient use of equity. EPS was 47.34円 (prior year 29.91円, +58.3%), with significant per-share earnings growth. [Financial Soundness] Equity Ratio improved to 72.2% (prior year 66.0%). Interest-bearing debt was ¥220.5B against cash of ¥768.8B, yielding net cash ¥548.3B, indicating a very strong balance sheet. Current ratio was 392.1% (prior year 384.2%) and quick ratio 378.4%, showing solid liquidity and sufficient ability to service short-term borrowings of ¥156.6B. [Cash Quality] Product warranty provisions were ¥18.1B (as a percentage of sales 4.9%), implying after-sales cost exposure, but ample cash balances provide a buffer. Notes and accounts receivable were ¥332.5B (sales ratio 89.4%), and inventories totaled ¥465.0B (sales ratio 124.9%), indicating elevated working capital levels; managing DSO and DIO will be important going forward.
Individual figures for Operating Cash Flow, Investing Cash Flow, and Financing Cash Flow were not disclosed, but balance sheet movements were used to infer cash trends. Cash and deposits increased to ¥768.8B (prior year ¥743.4B, +¥25.4B), suggesting solid cash generation from operations. Interest-bearing debt declined to ¥220.5B (prior year ¥238.3B, -¥17.8B), with long-term borrowings down to ¥64.0B (prior year ¥82.1B, -¥18.1B) reflecting repayment progress. Short-term borrowings remained stable at ¥156.6B (prior year ¥155.7B). Current assets rose to ¥1,600.6B (prior year ¥1,549.7B, +¥50.9B), and inventories increased to ¥465.0B (prior year ¥384.8B, +¥80.2B), indicating stock build for backlog fulfillment or parts procurement. Fixed assets edged down to ¥415.7B (prior year ¥423.3B, -¥7.6B), signaling restrained capital expenditure. Shareholders’ equity grew to ¥1,366.4B (prior year ¥1,302.3B, +¥64.1B) from retained earnings accumulation, strengthening internal reserves.
Earnings quality is high on an operating basis. Operating Income of ¥102.3B was supported by non-operating income of ¥11.3B (3.0% of sales), primarily ¥10.4B foreign exchange gains and ¥0.3B interest income, all within ordinary ranges. Non-operating expenses of ¥4.2B included ¥12.3B foreign exchange losses and ¥0.6B interest expense, with net FX impact modestly negative. Extraordinary items totaled -¥0.1B, limited to ¥0.1B impairment of fixed assets, indicating negligible one-off effects. The ¥7.1B difference between Ordinary Income ¥109.4B and Operating Income ¥102.3B is attributable to net non-operating items, supporting the view of a sustainable earnings base. Comprehensive income was ¥86.9B (of which owners of the parent ¥93.6B), exceeding Net Income ¥79.1B as foreign currency translation adjustments contributed ¥8.2B while valuation differences on available-for-sale securities were -¥0.3B. Operating income remains the core earnings driver, and accruals such as additions to product warranty provisions reflect business realities.
The full-year forecast remains unchanged: Revenue ¥1,590.2B (YoY +23.5%), Operating Income ¥381.1B (+22.3%), Ordinary Income ¥382.4B (+17.2%), Net Income attributable to owners of the parent ¥278.1B, and EPS ¥159.62. Progress at the end of Q1 was Revenue 23.4% (¥372.1B/¥1,590.2B), Operating Income 26.8% (¥102.3B/¥381.1B), Ordinary Income 28.6% (¥109.4B/¥382.4B), and Net Income 29.5% (¥82.1B/¥278.1B), exceeding the standard quarterly pace of 25% and indicating a strong start. Profit outperformance is attributable to gross margin improvement and expense control. No revisions to full-year guidance were made; order trends and currency/raw material cost environments in the second half will determine final results. Dividend forecast is unchanged at ¥0 per share, prioritizing balance sheet strengthening and growth investment through internal reserves.
The dividend forecast for the period is ¥0 per share, with a payout ratio of 0%, so no shareholder distribution is being made. The full-year forecast also maintains a ¥0 dividend, and retained earnings of ¥1,210.3B (prior year ¥1,157.7B, +¥52.6B) will be fully retained. Although cash holdings of ¥768.8B provide capacity for dividends, priority is being given to working capital needs (inventories +¥80.2B) and funding capital expenditure and R&D from internal resources. There were no share buybacks; total shareholder return is 0%. The emphasis on financial stability and growth investment is clear, but disclosure on shareholder return policy and guidance on potential dividend resumption would be welcomed.
Demand Concentration Risk: The Semiconductor & FPD-related Equipment business accounts for 99.6% of revenue and nearly all operating profit, creating high sensitivity to the industry investment cycle and customer capex patterns. While regional exposure is diversified (U.S. 29.8%, Taiwan 26.8%, China 24.8%), a downturn in semiconductor conditions could cause material swings in sales and profits.
Quality Cost / After-sales Cost Risk: Product warranty provisions of ¥18.1B (4.9% of sales) are high relative to industry norms, and increases in defects or after-sales service costs could pressure gross margin and operating cash flow. Warranty cost control and quality improvement are keys to stable earnings.
Working Capital Efficiency Risk: Inventories ¥465.0B (124.9% of sales) and receivables ¥332.5B (89.4% of sales) indicate elevated working capital levels; prolonged DSO and DIO would tie up funds and increase operating cash flow volatility. Managing order, shipment, and collection cycles is an ongoing priority.
Profitability & Returns
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Operating Margin | 27.5% | 8.8% (4.4%–14.3%) | +18.7pt |
| Net Margin | 21.3% | 7.3% (3.3%–10.6%) | +14.0pt |
Profitability materially exceeds the manufacturing industry median and is at a very high level within the sector.
Growth & Capital Efficiency
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Revenue Growth (YoY) | 12.5% | 6.6% (-0.3%–14.8%) | +5.9pt |
Growth also exceeds the industry median and sits in the upper quartile.
※ Source: Company aggregation
Confirmation of high profitability and growth: Q1 showed Operating Margin 27.5% (+195bp) and Net Margin 22.1% (+614bp), with Revenue +12.5%, Operating Income +21.2%, and Net Income +56.0%. Gross margin improvement to 43.1% suggests product mix and cost improvements and raises the possibility of upside to full-year results.
Strong financial position: Net cash ¥548.3B, Equity Ratio 72.2%, and Current Ratio 392.1% indicate very high financial soundness, providing resilience to economic fluctuations and short-term demand declines. Progress in repaying long-term borrowings and ability to roll over short-term debt appear sufficient.
Need to improve working capital efficiency: Inventories increased by ¥80.2B and receivables and inventory levels remain high, indicating working capital cash drag; improving inventory turnover and DSO is essential to enhance operating cash flow quality. The high level of product warranty provisions also makes quality-cost control critical to maintain margins over the medium to long term.
This report was auto-generated by AI analyzing XBRL earnings release data. It is not a recommendation to invest in any particular security. Industry benchmarks are reference information compiled by the company from public filings. Investment decisions are your responsibility; consult a professional as needed.